{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:26:54Z","timestamp":1791502014241,"version":"4.3.4"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2023-00209580"],"award-info":[{"award-number":["RS-2023-00209580"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2023-00208890"],"award-info":[{"award-number":["RS-2023-00208890"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder lacking any proven disease-modifying therapy. Drug repurposing offers a strategy to accelerate the development of treatments by utilizing agents originally approved for other indications. This review summarizes repurposed drugs investigated as disease-modifying therapies for MSA, spanning preclinical in vitro and animal studies and clinical trials. We focus on agents targeting key pathogenic mechanisms in MSA\u2014including \u03b1-synuclein aggregation (e.g., sirolimus\/rapamycin, rifampicin, lithium, nilotinib, epigallocatechin gallate), neuroinflammation (e.g., minocycline, intravenous immunoglobulin), mitochondrial dysfunction and excitotoxicity (e.g., ubiquinol, rasagiline, safinamide, riluzole), and impaired neurotrophic support (e.g., fluoxetine\/selective serotonin reuptake inhibitors, insulin, exendin-4). For each, we discuss mechanisms of action, experimental model outcomes, and clinical trial results. While numerous repurposed agents showed promise in MSA models, most failed to demonstrate significant disease-slowing effects in clinical trials. However, ubiquinol has recently emerged as a notable exception, with a Phase 2 randomized controlled trial showing a significant reduction in motor progression compared to placebo\u2014marking the first placebo-controlled evidence of disease modification in MSA. Limitations such as small sample sizes, late-stage patient enrollment, and tolerability issues (e.g., with lithium) have hampered past trials. Nonetheless, ongoing studies and emerging approaches such as combination therapies hold promise. Continued exploration of repurposed therapies, along with improved trial design and biomarker development, is warranted to finally achieve a disease-modifying treatment for MSA.<\/jats:p>","DOI":"10.1186\/s40035-026-00551-7","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T02:04:51Z","timestamp":1776737091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug repurposing for disease-modifying effects in multiple system atrophy"],"prefix":"10.1186","volume":"15","author":[{"given":"Seong Ho","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Young","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9931-8462","authenticated-orcid":false,"given":"Phil Hyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"issue":"14","key":"551_CR1","first-page":"1375","volume":"372","author":"A Fanciulli","year":"2015","unstructured":"Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372(14):1375\u20136.","journal-title":"N Engl J Med"},{"issue":"9","key":"551_CR2","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670\u20136.","journal-title":"Neurology"},{"issue":"1","key":"551_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00401-012-0977-5","volume":"124","author":"N Stefanova","year":"2012","unstructured":"Stefanova N, Kaufmann WA, Humpel C, Poewe W, Wenning GK. Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human \u03b1-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. Acta Neuropathol. 2012;124(1):51\u201365.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"551_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/S0002-9440(10)62307-3","volume":"166","author":"N Stefanova","year":"2005","unstructured":"Stefanova N, Reindl M, Neumann M, Haass C, Poewe W, Kahle PJ, et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol. 2005;166(3):869\u201376.","journal-title":"Am J Pathol"},{"issue":"7","key":"551_CR5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1474-4422(15)00058-7","volume":"14","author":"PA Low","year":"2015","unstructured":"Low PA, Reich SG, Jankovic J, Shults CW, Stern MB, Novak P, et al. Natural history of multiple system atrophy in the USA: a prospective cohort study. Lancet Neurol. 2015;14(7):710\u20139.","journal-title":"Lancet Neurol"},{"issue":"3","key":"551_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1474-4422(12)70327-7","volume":"12","author":"GK Wenning","year":"2013","unstructured":"Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 2013;12(3):264\u201374.","journal-title":"Lancet Neurol"},{"issue":"6","key":"551_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s12311-015-0728-y","volume":"15","author":"DJ Lin","year":"2016","unstructured":"Lin DJ, Hermann KL, Schmahmann JD. The diagnosis and natural history of multiple system atrophy, cerebellar type. Cerebellum. 2016;15(6):663\u201379.","journal-title":"Cerebellum"},{"issue":"8","key":"551_CR8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","volume":"20","author":"J Langedijk","year":"2015","unstructured":"Langedijk J, Mantel-Teeuwisse AK, Slijkerman DS, Schutjens MH. Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today. 2015;20(8):1027\u201334.","journal-title":"Drug Discov Today"},{"issue":"6","key":"551_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41583-023-00697-7","volume":"24","author":"N Stefanova","year":"2023","unstructured":"Stefanova N, Wenning GK. Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms. Nat Rev Neurosci. 2023;24(6):334\u201346.","journal-title":"Nat Rev Neurosci"},{"key":"551_CR10","first-page":"779","volume":"18","author":"N Cappoli","year":"2019","unstructured":"Cappoli N, Mezzogori D, Tabolacci E, Coletta I, Navarra P, Pani G, et al. The mTOR kinase inhibitor rapamycin enhances the expression and release of pro-inflammatory cytokine interleukin 6 modulating the activation of human microglial cells. Excli J. 2019;18:779\u201398.","journal-title":"Excli J"},{"issue":"1","key":"551_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s10286-019-00662-4","volume":"30","author":"A Ndayisaba","year":"2020","unstructured":"Ndayisaba A, Wenning GK. Inhibition of the mammalian target or rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophy. Clin Auton Res. 2020;30(1):7\u20138.","journal-title":"Clin Auton Res"},{"key":"551_CR12","first-page":"S441","volume":"33","author":"M Lopez-Cuina","year":"2018","unstructured":"Lopez-Cuina M, Guerin P, Bezard E, Meissner W, Fernagut P. Rapamycin for treating MSA: a preclinical proof of concept study [abstract]. Mov Disord. 2018;33:S441.","journal-title":"Mov Disord"},{"key":"551_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.559791","volume":"8","author":"M Fouka","year":"2020","unstructured":"Fouka M, Mavroeidi P, Tsaka G, Xilouri M. In search of effective treatments targeting \u03b1-synuclein toxicity in synucleinopathies: pros and cons. Front Cell Dev Biol. 2020;8:559791.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"551_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/mds.28923","volume":"37","author":"JA Palma","year":"2022","unstructured":"Palma JA, Martinez J, Millar Vernetti P, Ma T, Perez MA, Zhong J, et al. mTOR inhibition with sirolimus in multiple system atrophy: a randomized, double-blind, placebo-controlled futility trial and 1-year biomarker longitudinal analysis. Mov Disord. 2022;37(4):778\u201389.","journal-title":"Mov Disord"},{"issue":"11","key":"551_CR15","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.chembiol.2004.08.025","volume":"11","author":"J Li","year":"2004","unstructured":"Li J, Zhu M, Rajamani S, Uversky VN, Fink AL. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol. 2004;11(11):1513\u201321.","journal-title":"Chem Biol"},{"issue":"13","key":"551_CR16","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/WNR.0b013e32830b3661","volume":"19","author":"K Ubhi","year":"2008","unstructured":"Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. NeuroReport. 2008;19(13):1271\u20136.","journal-title":"NeuroReport"},{"issue":"3","key":"551_CR17","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(13)70301-6","volume":"13","author":"PA Low","year":"2014","unstructured":"Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, et al. Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(3):268\u201375.","journal-title":"Lancet Neurol"},{"issue":"8","key":"551_CR18","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1093\/cid\/ciz1071","volume":"71","author":"EM Svensson","year":"2019","unstructured":"Svensson EM, Dian S, Te Brake L, Ganiem AR, Yunivita V, van Laarhoven A, et al. Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials. Clin Infect Dis. 2019;71(8):1817\u201323.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"551_CR19","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1093\/infdis\/jiaf178","volume":"232","author":"N Abdelgawad","year":"2025","unstructured":"Abdelgawad N, Wasserman S, Gausi K, Davis A, Stek C, Wiesner L, et al. Population pharmacokinetics of rifampicin in plasma and cerebrospinal fluid in adults with tuberculosis meningitis. J Infect Dis. 2025;232(2):e234\u201341.","journal-title":"J Infect Dis"},{"key":"551_CR20","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.parkreldis.2020.01.010","volume":"73","author":"A Heras-Garvin","year":"2020","unstructured":"Heras-Garvin A, Stefanova N. MSA: from basic mechanisms to experimental therapeutics. Parkinsonism Relat Disord. 2020;73:94\u2013104.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"551_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/00207454.2012.729234","volume":"123","author":"XZ Li","year":"2013","unstructured":"Li XZ, Chen XP, Zhao K, Bai LM, Zhang H, Zhou XP. Therapeutic effects of valproate combined with lithium carbonate on MPTP-induced parkinsonism in mice: possible mediation through enhanced autophagy. Int J Neurosci. 2013;123(2):73\u20139.","journal-title":"Int J Neurosci"},{"key":"551_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-015-0222-y","volume":"16","author":"L Hou","year":"2015","unstructured":"Hou L, Xiong N, Liu L, Huang J, Han C, Zhang G, et al. Lithium protects dopaminergic cells from rotenone toxicity via autophagy enhancement. BMC Neurosci. 2015;16:82.","journal-title":"BMC Neurosci"},{"issue":"10","key":"551_CR23","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/jnr.22700","volume":"89","author":"YH Kim","year":"2011","unstructured":"Kim YH, Rane A, Lussier S, Andersen JK. Lithium protects against oxidative stress-mediated cell death in \u03b1-synuclein-overexpressing in vitro and in vivo models of Parkinson\u2019s disease. J Neurosci Res. 2011;89(10):1666\u201375.","journal-title":"J Neurosci Res"},{"issue":"2","key":"551_CR24","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s00415-012-6655-7","volume":"260","author":"F Sacc\u00e0","year":"2013","unstructured":"Sacc\u00e0 F, Marsili A, Quarantelli M, Brescia Morra V, Brunetti A, Carbone R, et al. A randomized clinical trial of lithium in multiple system atrophy. J Neurol. 2013;260(2):458\u201361.","journal-title":"J Neurol"},{"issue":"4","key":"551_CR25","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1007\/s12035-019-01849-6","volume":"57","author":"M Ettcheto","year":"2020","unstructured":"Ettcheto M, Cano A, Manzine PR, Busquets O, Verdaguer E, Castro-Torres RD, et al. Epigallocatechin-3-gallate (EGCG) improves cognitive deficits aggravated by an obesogenic diet through modulation of unfolded protein response in APPswe\/PS1dE9 mice. Mol Neurobiol. 2020;57(4):1814\u201327.","journal-title":"Mol Neurobiol"},{"issue":"24","key":"551_CR26","doi-asserted-by":"publisher","first-page":"16419","DOI":"10.1074\/jbc.M600617200","volume":"281","author":"DF Obregon","year":"2006","unstructured":"Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, et al. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem. 2006;281(24):16419\u201327.","journal-title":"J Biol Chem"},{"key":"551_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.718188","volume":"15","author":"L Fernandes","year":"2021","unstructured":"Fernandes L, Cardim-Pires TR, Foguel D, Palhano FL. Green tea polyphenol epigallocatechin-gallate in amyloid aggregation and neurodegenerative diseases. Front Neurosci. 2021;15:718188.","journal-title":"Front Neurosci"},{"issue":"6","key":"551_CR28","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nsmb.1437","volume":"15","author":"DE Ehrnhoefer","year":"2008","unstructured":"Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, Lurz R, et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol. 2008;15(6):558\u201366.","journal-title":"Nat Struct Mol Biol"},{"issue":"4","key":"551_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00702-016-1507-8","volume":"123","author":"J Levin","year":"2016","unstructured":"Levin J, Maa\u00df S, Schuberth M, Respondek G, Paul F, Mansmann U, et al. The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach. J Neural Transm. 2016;123(4):439\u201345.","journal-title":"J Neural Transm"},{"issue":"8","key":"551_CR30","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S1474-4422(19)30141-3","volume":"18","author":"J Levin","year":"2019","unstructured":"Levin J, Maa\u00df S, Schuberth M, Giese A, Oertel WH, Poewe W, et al. Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2019;18(8):724\u201335.","journal-title":"Lancet Neurol"},{"key":"551_CR31","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000259","volume":"5","author":"ML Hebron","year":"2014","unstructured":"Hebron ML, Lonskaya I, Olopade P, Selby ST, Pagan F, Moussa CE. Tyrosine kinase inhibition regulates early systemic immune changes and modulates the neuroimmune response in \u03b1-synucleinopathy. J Clin Cell Immunol. 2014;5:259.","journal-title":"J Clin Cell Immunol"},{"issue":"16","key":"551_CR32","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1093\/hmg\/ddt192","volume":"22","author":"ML Hebron","year":"2013","unstructured":"Hebron ML, Lonskaya I, Moussa CE. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of \u03b1-synuclein in Parkinson\u2019s disease models. Hum Mol Genet. 2013;22(16):3315\u201328.","journal-title":"Hum Mol Genet"},{"key":"551_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/srep04874","volume":"4","author":"SS Karuppagounder","year":"2014","unstructured":"Karuppagounder SS, Brahmachari S, Lee Y, Dawson VL, Dawson TM, Ko HS. The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson\u2019s disease. Sci Rep. 2014;4:4874.","journal-title":"Sci Rep"},{"issue":"8","key":"551_CR34","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1172\/JCI85456","volume":"126","author":"S Brahmachari","year":"2016","unstructured":"Brahmachari S, Ge P, Lee SH, Kim D, Karuppagounder SS, Kumar M, et al. Activation of tyrosine kinase c-Abl contributes to \u03b1-synuclein-induced neurodegeneration. J Clin Invest. 2016;126(8):2970\u201388.","journal-title":"J Clin Invest"},{"issue":"7","key":"551_CR35","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/mds.28034","volume":"35","author":"M Lopez-Cuina","year":"2020","unstructured":"Lopez-Cuina M, Guerin PA, Canron MH, Delamarre A, Dehay B, Bezard E, et al. Nilotinib fails to prevent synucleinopathy and cell loss in a mouse model of Multiple System Atrophy. Mov Disord. 2020;35(7):1163\u201372.","journal-title":"Mov Disord"},{"issue":"3","key":"551_CR36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JPD-160867","volume":"6","author":"F Pagan","year":"2016","unstructured":"Pagan F, Hebron M, Valadez EH, Torres-Yaghi Y, Huang X, Mills RR, et al. Nilotinib effects in Parkinson\u2019s disease and dementia with Lewy bodies. J Parkinsons Dis. 2016;6(3):503\u201317.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"551_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","volume":"77","author":"FL Pagan","year":"2020","unstructured":"Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, et al. Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77(3):309\u201317.","journal-title":"JAMA Neurol"},{"key":"551_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113810","volume":"344","author":"JE Lee","year":"2021","unstructured":"Lee JE, Kim HN, Kim DY, Shin YJ, Shin JY, Lee PH. Memantine exerts neuroprotective effects by modulating \u03b1-synuclein transmission in a parkinsonian model. Exp Neurol. 2021;344:113810.","journal-title":"Exp Neurol"},{"issue":"7706","key":"551_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","volume":"557","author":"C Peng","year":"2018","unstructured":"Peng C, Gathagan RJ, Covell DJ, Medellin C, Stieber A, Robinson JL, et al. Cellular milieu imparts distinct pathological \u03b1-synuclein strains in \u03b1-synucleinopathies. Nature. 2018;557(7706):558\u201363.","journal-title":"Nature"},{"key":"551_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2015.00437","volume":"9","author":"BD Vieira","year":"2015","unstructured":"Vieira BD, Radford RA, Chung RS, Guillemin GJ, Pountney DL. Neuroinflammation in multiple system atrophy: response to and cause of \u03b1-synuclein aggregation. Front Cell Neurosci. 2015;9:437.","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"551_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/glia.20051","volume":"48","author":"JK Ryu","year":"2004","unstructured":"Ryu JK, Franciosi S, Sattayaprasert P, Kim SU, McLarnon JG. Minocycline inhibits neuronal death and glial activation induced by beta-amyloid peptide in rat hippocampus. Glia. 2004;48(1):85\u201390.","journal-title":"Glia"},{"issue":"4","key":"551_CR42","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1161\/01.STR.0000206281.77178.ac","volume":"37","author":"MA Yenari","year":"2006","unstructured":"Yenari MA, Xu L, Tang XN, Qiao Y, Giffard RG. Microglia potentiate damage to blood-brain barrier constituents: improvement by minocycline in vivo and in vitro. Stroke. 2006;37(4):1087\u201393.","journal-title":"Stroke"},{"issue":"2","key":"551_CR43","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.bbr.2008.09.040","volume":"196","author":"HS Kim","year":"2009","unstructured":"Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009;196(2):168\u201379.","journal-title":"Behav Brain Res"},{"issue":"2","key":"551_CR44","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bph.12139","volume":"169","author":"N Garrido-Mesa","year":"2013","unstructured":"Garrido-Mesa N, Zarzuelo A, G\u00e1lvez J. Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337\u201352.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"551_CR45","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/jnr.20233","volume":"78","author":"N Stefanova","year":"2004","unstructured":"Stefanova N, Mitschnigg M, Ghorayeb I, Diguet E, Geser F, Tison F, et al. Failure of neuronal protection by inhibition of glial activation in a rat model of striatonigral degeneration. J Neurosci Res. 2004;78(1):87\u201391.","journal-title":"J Neurosci Res"},{"issue":"1","key":"551_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/mds.22732","volume":"25","author":"R Dodel","year":"2010","unstructured":"Dodel R, Spottke A, Gerhard A, Reuss A, Reinecker S, Schimke N, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord. 2010;25(1):97\u2013107.","journal-title":"Mov Disord"},{"issue":"1","key":"551_CR47","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s13311-015-0391-5","volume":"13","author":"JD L\u00fcnemann","year":"2016","unstructured":"L\u00fcnemann JD, Quast I, Dalakas MC. Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics. 2016;13(1):34\u201346.","journal-title":"Neurotherapeutics"},{"key":"551_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-12-131","volume":"12","author":"P Novak","year":"2012","unstructured":"Novak P, Williams A, Ravin P, Zurkiya O, Abduljalil A, Novak V. Treatment of multiple system atrophy using intravenous immunoglobulin. BMC Neurol. 2012;12:131.","journal-title":"BMC Neurol"},{"issue":"1","key":"551_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-016-0409-1","volume":"5","author":"E Valera","year":"2017","unstructured":"Valera E, Spencer B, Fields JA, Trinh I, Adame A, Mante M, et al. Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy. Acta Neuropathol Commun. 2017;5(1):2.","journal-title":"Acta Neuropathol Commun"},{"key":"551_CR50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.neuropharm.2017.01.028","volume":"117","author":"I Segura-Ulate","year":"2017","unstructured":"Segura-Ulate I, Yang B, Vargas-Medrano J, Perez RG. FTY720 (Fingolimod) reverses \u03b1-synuclein-induced downregulation of brain-derived neurotrophic factor mRNA in OLN-93 oligodendroglial cells. Neuropharmacology. 2017;117:149\u201357.","journal-title":"Neuropharmacology"},{"key":"551_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107701","volume":"158","author":"J Vargas-Medrano","year":"2019","unstructured":"Vargas-Medrano J, Segura-Ulate I, Yang B, Chinnasamy R, Arterburn JB, Perez RG. FTY720-Mitoxy reduces toxicity associated with MSA-like \u03b1-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures. Neuropharmacology. 2019;158:107701.","journal-title":"Neuropharmacology"},{"issue":"2","key":"551_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s00702-020-02158-2","volume":"127","author":"MJ Glat","year":"2020","unstructured":"Glat MJ, Stefanova N, Wenning GK, Offen D. Genes to treat excitotoxicity ameliorate the symptoms of the disease in mice models of multiple system atrophy. J Neural Transm. 2020;127(2):205\u201312.","journal-title":"J Neural Transm"},{"issue":"6","key":"551_CR53","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00702-016-1545-2","volume":"123","author":"KA Jellinger","year":"2016","unstructured":"Jellinger KA, Wenning GK. Multiple system atrophy: pathogenic mechanisms and biomarkers. J Neural Transm. 2016;123(6):555\u201372.","journal-title":"J Neural Transm"},{"issue":"3","key":"551_CR54","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1212115","volume":"369","author":"Multiple-System Atrophy Research Collaboration","year":"2013","unstructured":"Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med. 2013;369(3):233\u201344.","journal-title":"N Engl J Med"},{"key":"551_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117623","volume":"429","author":"KJ Porto","year":"2021","unstructured":"Porto KJ, Hirano M, Mitsui J, Chikada A, Matsukawa T, Ishiura H, et al. COQ2 V393A confers high risk susceptibility for multiple system atrophy in East Asian population. J Neurol Sci. 2021;429:117623.","journal-title":"J Neurol Sci"},{"issue":"7","key":"551_CR56","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/jnen\/nlw037","volume":"75","author":"E Barca","year":"2016","unstructured":"Barca E, Kleiner G, Tang G, Ziosi M, Tadesse S, Masliah E, et al. Decreased coenzyme Q10 levels in multiple system atrophy cerebellum. J Neuropathol Exp Neurol. 2016;75(7):663\u201372.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"551_CR57","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1016\/j.bbadis.2018.09.018","volume":"1864","author":"G Monzio Compagnoni","year":"2018","unstructured":"Monzio Compagnoni G, Kleiner G, Bordoni A, Fortunato F, Ronchi D, Salani S, et al. Mitochondrial dysfunction in fibroblasts of multiple system atrophy. Biochimica et Biophysica Acta (BBA). 2018;1864(12):3588\u201397.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"1","key":"551_CR58","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10048-018-0563-7","volume":"20","author":"T Yasuda","year":"2019","unstructured":"Yasuda T, Matsukawa T, Mitsui J, Tsuji S. Oxygen consumption rate for evaluation of COQ2 variants associated with multiple system atrophy. Neurogenetics. 2019;20(1):51\u20132.","journal-title":"Neurogenetics"},{"issue":"2","key":"551_CR59","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00424-010-0809-1","volume":"460","author":"A Lau","year":"2010","unstructured":"Lau A, Tymianski M. Glutamate receptors, neurotoxicity and neurodegeneration. Pflugers Arch. 2010;460(2):525\u201342.","journal-title":"Pflugers Arch"},{"key":"551_CR60","first-page":"597","volume":"5","author":"M Spindler","year":"2009","unstructured":"Spindler M, Beal MF, Henchcliffe C. Coenzyme Q10 effects in neurodegenerative disease. Neuropsychiatr Dis Treat. 2009;5:597\u2013610.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"10","key":"551_CR61","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/archneur.59.10.1541","volume":"59","author":"CW Shults","year":"2002","unstructured":"Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541\u201350.","journal-title":"Arch Neurol"},{"issue":"1","key":"551_CR62","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","volume":"68","author":"Ninds Net-PD Investigators","year":"2007","unstructured":"Ninds Net-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68(1):20\u20138.","journal-title":"Neurology"},{"issue":"3","key":"551_CR63","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12311-017-0846-9","volume":"16","author":"J Mitsui","year":"2017","unstructured":"Mitsui J, Koguchi K, Momose T, Takahashi M, Matsukawa T, Yasuda T, et al. Three-year follow-up of high-dose ubiquinol supplementation in a case of familial multiple system atrophy with compound heterozygous COQ2 mutations. Cerebellum. 2017;16(3):664\u201372.","journal-title":"Cerebellum"},{"key":"551_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101920","volume":"59","author":"J Mitsui","year":"2023","unstructured":"Mitsui J, Matsukawa T, Uemura Y, Kawahara T, Chikada A, Porto KJL, et al. High-dose ubiquinol supplementation in multiple-system atrophy: a multicentre, randomised, double-blinded, placebo-controlled phase 2 trial. eClinicalMedicine. 2023;59:101920.","journal-title":"eClinicalMedicine"},{"issue":"18","key":"551_CR65","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.2174\/092986710791163939","volume":"17","author":"BC Cheah","year":"2010","unstructured":"Cheah BC, Vucic S, Krishnan AV, Kiernan MC. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr Med Chem. 2010;17(18):1942\u20132199.","journal-title":"Curr Med Chem"},{"issue":"10","key":"551_CR66","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1111\/j.1460-9568.2008.06211.x","volume":"27","author":"N Lamanauskas","year":"2008","unstructured":"Lamanauskas N, Nistri A. Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci. 2008;27(10):2501\u201314.","journal-title":"Eur J Neurosci"},{"issue":"8","key":"551_CR67","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00702-004-0245-5","volume":"112","author":"C Scherfler","year":"2005","unstructured":"Scherfler C, Sather T, Diguet E, Stefanova N, Puschban Z, Tison F, et al. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (Parkinson variant of multiple system atrophy). J Neural Transm. 2005;112(8):1025\u201333.","journal-title":"J Neural Transm"},{"issue":"Pt 1","key":"551_CR68","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1093\/brain\/awn291","volume":"132","author":"G Bensimon","year":"2009","unstructured":"Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Leigh PN. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain. 2009;132(Pt 1):156\u201371.","journal-title":"Brain"},{"issue":"10","key":"551_CR69","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1111\/j.1468-1331.2006.01452.x","volume":"13","author":"K Seppi","year":"2006","unstructured":"Seppi K, Peralta C, Diem-Zangerl A, Puschban Z, Mueller J, Poewe W, et al. Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol. 2006;13(10):1146\u20138.","journal-title":"Eur J Neurol"},{"key":"551_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1117491","volume":"15","author":"YJ Shin","year":"2023","unstructured":"Shin YJ, Kim YJ, Lee JE, Kim YS, Lee JW, Kim H, et al. Uric acid regulates \u03b1-synuclein transmission in Parkinsonian models. Front Aging Neurosci. 2023;15:1117491.","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"551_CR71","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1002\/mds.23556","volume":"26","author":"JE Lee","year":"2011","unstructured":"Lee JE, Song SK, Sohn YH, Lee PH. Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord. 2011;26(8):1533\u20136.","journal-title":"Mov Disord"},{"issue":"6","key":"551_CR72","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/acn3.51073","volume":"7","author":"HS Yoo","year":"2020","unstructured":"Yoo HS, Chung SJ, Lee YH, Ye BS, Sohn YH, Kwon H, et al. Urate is closely linked to white matter integrity in multiple system atrophy. Ann Clin Transl Neurol. 2020;7(6):1029\u201339.","journal-title":"Ann Clin Transl Neurol"},{"issue":"5","key":"551_CR73","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/cpt.2082","volume":"109","author":"J Jung Lee","year":"2021","unstructured":"Jung Lee J, Han Yoon J, Jin Kim S, Soo Yoo H, Jong Chung S, Hyun Lee Y, et al. Inosine 5\u2019-monophosphate to raise serum uric acid level in multiple system atrophy (IMPROVE-MSA study). Clin Pharmacol Ther. 2021;109(5):1274\u201381.","journal-title":"Clin Pharmacol Ther"},{"issue":"13","key":"551_CR74","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","volume":"361","author":"CW Olanow","year":"2009","unstructured":"Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson\u2019s disease. N Engl J Med. 2009;361(13):1268\u201378.","journal-title":"N Engl J Med"},{"issue":"2","key":"551_CR75","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.expneurol.2007.11.022","volume":"210","author":"N Stefanova","year":"2008","unstructured":"Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol. 2008;210(2):421\u20137.","journal-title":"Exp Neurol"},{"issue":"2","key":"551_CR76","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1474-4422(14)70288-1","volume":"14","author":"W Poewe","year":"2015","unstructured":"Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, et al. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2015;14(2):145\u201352.","journal-title":"Lancet Neurol"},{"issue":"5","key":"551_CR77","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/mds.30162","volume":"40","author":"RMA de Bie","year":"2025","unstructured":"de Bie RMA, Katzenschlager R, Swinnen BEKS, Peball M, Lim S-Y, Mestre TA, et al. Update on treatments for parkinson\u2019s disease motor fluctuations \u2013 an international Parkinson and movement disorder society evidence-based medicine review. Mov Disord. 2025;40(5):776\u201394.","journal-title":"Mov Disord"},{"issue":"6","key":"551_CR78","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2217\/nmt.15.46","volume":"5","author":"M Fabbri","year":"2015","unstructured":"Fabbri M, Rosa MM, Abreu D, Ferreira JJ. Clinical pharmacology review of safinamide for the treatment of Parkinson\u2019s disease. Neurodegener Dis Manag. 2015;5(6):481\u201396.","journal-title":"Neurodegener Dis Manag"},{"issue":"2","key":"551_CR79","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pharmthera.2013.01.004","volume":"138","author":"SJ Allen","year":"2013","unstructured":"Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol Ther. 2013;138(2):155\u201375.","journal-title":"Pharmacol Ther"},{"key":"551_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(11)70066-9","volume":"18","author":"F Zhang","year":"2012","unstructured":"Zhang F, Zhou H, Wilson BC, Shi JS, Hong JS, Gao HM. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism Relat Disord. 2012;18:S213\u20137.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"551_CR81","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.expneurol.2012.01.008","volume":"234","author":"K Ubhi","year":"2012","unstructured":"Ubhi K, Inglis C, Mante M, Patrick C, Adame A, Spencer B, et al. Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of \u03b1-synucleinopathy. Exp Neurol. 2012;234(2):405\u201316.","journal-title":"Exp Neurol"},{"issue":"2","key":"551_CR82","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/glia.22610","volume":"62","author":"E Valera","year":"2014","unstructured":"Valera E, Ubhi K, Mante M, Rockenstein E, Masliah E. Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy. Glia. 2014;62(2):317\u201337.","journal-title":"Glia"},{"issue":"7","key":"551_CR83","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1002\/mds.28569","volume":"36","author":"O Rascol","year":"2021","unstructured":"Rascol O, Cochen de Cock V, Pavy-Le Traon A, Foubert-Samier A, Thalamas C, Sommet A, et al. Fluoxetine for the symptomatic treatment of multiple system atrophy: the MSA-FLUO trial. Mov Disord. 2021;36(7):1704\u201311.","journal-title":"Mov Disord"},{"key":"551_CR84","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.parkreldis.2017.12.011","volume":"48","author":"EA Coon","year":"2018","unstructured":"Coon EA, Ahlskog JE, Silber MH, Fealey RD, Benarroch EE, Sandroni P, et al. Do selective serotonin reuptake inhibitors improve survival in multiple system atrophy? Parkinsonism Relat Disord. 2018;48:51\u20133.","journal-title":"Parkinsonism Relat Disord"},{"key":"551_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.02.005","volume":"118","author":"F Bassil","year":"2014","unstructured":"Bassil F, Fernagut PO, Bezard E, Meissner WG. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification? Prog Neurobiol. 2014;118:1\u201318.","journal-title":"Prog Neurobiol"},{"issue":"2","key":"551_CR86","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1210\/jc.2011-1802","volume":"97","author":"E Shemesh","year":"2012","unstructured":"Shemesh E, Rudich A, Harman-Boehm I, Cukierman-Yaffe T. Effect of intranasal insulin on cognitive function: a systematic review. J Clin Endocrinol Metab. 2012;97(2):366\u201376.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"551_CR87","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/brain\/awx044","volume":"140","author":"F Bassil","year":"2017","unstructured":"Bassil F, Canron MH, Vital A, Bezard E, Li Y, Greig NH, et al. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain. 2017;140(5):1420\u201336.","journal-title":"Brain"},{"issue":"2","key":"551_CR88","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.parkreldis.2013.11.005","volume":"20","author":"A Numao","year":"2014","unstructured":"Numao A, Suzuki K, Miyamoto M, Miyamoto T, Hirata K. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson\u2019s disease, multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 2014;20(2):212\u20136.","journal-title":"Parkinsonism Relat Disord"},{"issue":"15","key":"551_CR89","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1002\/mds.23320","volume":"25","author":"MT Pellecchia","year":"2010","unstructured":"Pellecchia MT, Pivonello R, Longo K, Manfredi M, Tessitore A, Amboni M, et al. Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system. Mov Disord. 2010;25(15):2621\u20136.","journal-title":"Mov Disord"},{"issue":"4","key":"551_CR90","doi-asserted-by":"publisher","first-page":"e0214364","DOI":"10.1371\/journal.pone.0214364","volume":"14","author":"P Novak","year":"2019","unstructured":"Novak P, Pimentel Maldonado DA, Novak V. Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: a double-blinded placebo-controlled pilot study. PLoS One. 2019;14(4):e0214364.","journal-title":"PLoS One"},{"issue":"8","key":"551_CR91","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.21501","volume":"22","author":"B Holmberg","year":"2007","unstructured":"Holmberg B, Johansson JO, Poewe W, Wenning G, Quinn NP, Mathias C, et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord. 2007;22(8):1138\u201344.","journal-title":"Mov Disord"},{"issue":"5","key":"551_CR92","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/ana.70004","volume":"98","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Wiegand M, Ismail C, Lameirinhas A, Yarnall A, et al. Exenatide once weekly in the treatment of patients with multiple system atrophy. Ann Neurol. 2025;98(5):991\u20131003.","journal-title":"Ann Neurol"},{"issue":"4","key":"551_CR93","doi-asserted-by":"publisher","first-page":"337","DOI":"10.5607\/en.2014.23.4.337","volume":"23","author":"JH Wong","year":"2014","unstructured":"Wong JH, Halliday GM, Kim WS. Exploring myelin dysfunction in multiple system atrophy. Exp Neurobiol. 2014;23(4):337\u201344.","journal-title":"Exp Neurobiol"},{"issue":"1","key":"551_CR94","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00401-016-1572-y","volume":"132","author":"B Ettle","year":"2016","unstructured":"Ettle B, Kerman BE, Valera E, Gillmann C, Schlachetzki JC, Reiprich S, et al. \u03b1-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy. Acta Neuropathol. 2016;132(1):59\u201375.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"551_CR95","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/ejn.16215","volume":"59","author":"L M\u00e9sz\u00e1ros","year":"2024","unstructured":"M\u00e9sz\u00e1ros L, Himmler M, Schneider Y, Arnold P, D\u00f6rje F, Schubert DW, et al. Sobetirome rescues \u03b1-synuclein-mediated demyelination in an in vitro model of multiple system atrophy. Eur J Neurosci. 2024;59(2):308\u201315.","journal-title":"Eur J Neurosci"},{"issue":"6","key":"551_CR96","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1002\/mds.29005","volume":"37","author":"GK Wenning","year":"2022","unstructured":"Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2022;37(6):1131\u201348.","journal-title":"Mov Disord"},{"issue":"7","key":"551_CR97","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/mds.26220","volume":"30","author":"H Ling","year":"2015","unstructured":"Ling H, Asi YT, Petrovic IN, Ahmed Z, Prashanth LK, Hazrati LN, et al. Minimal change multiple system atrophy: an aggressive variant? Mov Disord. 2015;30(7):960\u20137.","journal-title":"Mov Disord"},{"issue":"5","key":"551_CR98","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/nan.12195","volume":"41","author":"H McCann","year":"2015","unstructured":"McCann H, McGeachie AB, Silberstein P, Lewis SJ, Halliday GM. Restricted disease propagation in multiple system atrophy with prolonged survival. Neuropathol Appl Neurobiol. 2015;41(5):681\u20135.","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"9","key":"551_CR99","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/mds.25115","volume":"27","author":"IN Petrovic","year":"2012","unstructured":"Petrovic IN, Ling H, Asi Y, Ahmed Z, Kukkle PL, Hazrati LN, et al. Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord. 2012;27(9):1186\u201390.","journal-title":"Mov Disord"},{"issue":"2","key":"551_CR100","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10286-021-00782-w","volume":"31","author":"JA Palma","year":"2021","unstructured":"Palma JA, Vernetti PM, Perez MA, Krismer F, Seppi K, Fanciulli A, et al. Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement. Clin Auton Res. 2021;31(2):157\u201364.","journal-title":"Clin Auton Res"},{"issue":"3","key":"551_CR101","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00401-019-02014-y","volume":"138","author":"P Mavroeidi","year":"2019","unstructured":"Mavroeidi P, Arvanitaki F, Karakitsou AK, Vetsi M, Kloukina I, Zweckstetter M, et al. Endogenous oligodendroglial alpha-synuclein and TPPP\/p25\u03b1 orchestrate alpha-synuclein pathology in experimental multiple system atrophy models. Acta Neuropathol. 2019;138(3):415\u201341.","journal-title":"Acta Neuropathol"},{"issue":"4","key":"551_CR102","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.2353\/ajpath.2007.070201","volume":"171","author":"YJ Song","year":"2007","unstructured":"Song YJ, Lundvig DM, Huang Y, Gai WP, Blumbergs PC, H\u00f8jrup P, et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol. 2007;171(4):1291\u2013303.","journal-title":"Am J Pathol"},{"issue":"1","key":"551_CR103","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00401-021-02316-0","volume":"142","author":"N Ferreira","year":"2021","unstructured":"Ferreira N, Gram H, Sorrentino ZA, Gregersen E, Schmidt SI, Reimer L, et al. Multiple System Atrophy-associated oligodendroglial protein p25\u03b1 stimulates formation of novel \u03b1-synuclein strain with enhanced neurodegenerative potential. Acta Neuropathol. 2021;142(1):87\u2013115.","journal-title":"Acta Neuropathol"},{"key":"551_CR104","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.neuropharm.2018.08.002","volume":"140","author":"C Brandt","year":"2018","unstructured":"Brandt C, Hillmann P, Noack A, R\u00f6mermann K, \u00d6hler LA, Rageot D, et al. The novel, catalytic mTORC1\/2 inhibitor PQR620 and the PI3K\/mTORC1\/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. Neuropharmacology. 2018;140:107\u201320.","journal-title":"Neuropharmacology"},{"issue":"1","key":"551_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3575","volume":"4","author":"L Bousset","year":"2013","unstructured":"Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, et al. Structural and functional characterization of two alpha-synuclein strains. Nat Commun. 2013;4(1):2575.","journal-title":"Nat Commun"},{"issue":"1","key":"551_CR106","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41593-019-0541-x","volume":"23","author":"A Lau","year":"2020","unstructured":"Lau A, So RWL, Lau HHC, Sang JC, Ruiz-Riquelme A, Fleck SC, et al. \u03b1-Synuclein strains target distinct brain regions and cell types. Nat Neurosci. 2020;23(1):21\u201331.","journal-title":"Nat Neurosci"},{"issue":"6","key":"551_CR107","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s00401-020-02157-3","volume":"139","author":"A Van der Perren","year":"2020","unstructured":"Van der Perren A, Gelders G, Fenyi A, Bousset L, Brito F, Peelaerts W, et al. The structural differences between patient-derived \u03b1-synuclein strains dictate characteristics of Parkinson\u2019s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol. 2020;139(6):977\u20131000.","journal-title":"Acta Neuropathol"},{"issue":"7794","key":"551_CR108","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41586-020-1984-7","volume":"578","author":"M Shahnawaz","year":"2020","unstructured":"Shahnawaz M, Mukherjee A, Pritzkow S, Mendez N, Rabadia P, Liu X, et al. Discriminating \u03b1-synuclein strains in Parkinson\u2019s disease and multiple system atrophy. Nature. 2020;578(7794):273\u20137.","journal-title":"Nature"},{"issue":"17","key":"551_CR109","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.1073\/pnas.0910723107","volume":"107","author":"J Bieschke","year":"2010","unstructured":"Bieschke J, Russ J, Friedrich RP, Ehrnhoefer DE, Wobst H, Neugebauer K, et al. EGCG remodels mature \u03b1-synuclein and amyloid-\u03b2 fibrils and reduces cellular toxicity. Proc Natl Acad Sci U S A. 2010;107(17):7710\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"551_CR110","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10286-024-01028-1","volume":"34","author":"F Leys","year":"2024","unstructured":"Leys F, Eschlb\u00f6ck S, Campese N, Mahlknecht P, Peball M, Goebel G, et al. Sex-related differences in the clinical presentation of multiple system atrophy. Clin Auton Res. 2024;34(2):253\u201368.","journal-title":"Clin Auton Res"},{"key":"551_CR111","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.autneu.2019.04.002","volume":"219","author":"EA Coon","year":"2019","unstructured":"Coon EA, Nelson RM, Sletten DM, Suarez MD, Ahlskog JE, Benarroch EE, et al. Sex and gender influence symptom manifestation and survival in multiple system atrophy. Auton Neurosci. 2019;219:49\u201352.","journal-title":"Auton Neurosci"},{"issue":"14","key":"551_CR112","doi-asserted-by":"publisher","first-page":"e1328","DOI":"10.1212\/WNL.0000000000008194","volume":"93","author":"MA Schwarzschild","year":"2019","unstructured":"Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, et al. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019;93(14):e1328\u201338.","journal-title":"Neurology"},{"issue":"5","key":"551_CR113","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/ene.14152","volume":"27","author":"K Baik","year":"2020","unstructured":"Baik K, Chung SJ, Yoo HS, Lee YH, Jung JH, Sohn YH, et al. Sex-dependent association of urate on the patterns of striatal dopamine depletion in Parkinson\u2019s disease. Eur J Neurol. 2020;27(5):773\u20138.","journal-title":"Eur J Neurol"},{"key":"551_CR114","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.parkreldis.2018.03.023","volume":"52","author":"Y Lee","year":"2018","unstructured":"Lee Y, Park Y-H, Lee JJ, Sohn YH, Lee J-M, Lee PH. Gender-specific effect of uric acid on resting-state functional networks in de novo Parkinson\u2019s disease. Parkinsonism Relat Disord. 2018;52:49\u201354.","journal-title":"Parkinsonism Relat Disord"},{"issue":"10","key":"551_CR115","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1111\/ene.14337","volume":"27","author":"JH Jung","year":"2020","unstructured":"Jung JH, Chung SJ, Yoo HS, Lee YH, Baik K, Ye BS, et al. Sex-specific association of urate and levodopa-induced dyskinesia in Parkinson\u2019s disease. Eur J Neurol. 2020;27(10):1948\u201356.","journal-title":"Eur J Neurol"},{"issue":"12","key":"551_CR116","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1038\/s41591-024-03270-6","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, et al. Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024;30(12):3669\u201375.","journal-title":"Nat Med"},{"key":"551_CR117","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1212\/WNL.0000000000212526","volume":"104","author":"D Stamler","year":"2025","unstructured":"Stamler D, Wong C, Diaz PT, Bradbury M, Lucas C, Claassen D. Topline data from a randomized, double blind, placebo controlled phase 2 study of ATH434 in multiple system atrophy (S37.008). Neurology. 2025;104:5685.","journal-title":"Neurology"}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-026-00551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-026-00551-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-026-00551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:13:00Z","timestamp":1776744780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40035-026-00551-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":117,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1186\/s40035-026-00551-7","relation":{},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no competing interests to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}